Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Editas Medicine (EDIT) over the last 10 years, with Dec 2024 value amounting to $341.6 million.

  • Editas Medicine's Liabilities and Shareholders Equity fell 38.41% to $201.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 38.40%. This contributed to the annual value of $341.6 million for FY2024, which is 31.57% down from last year.
  • Editas Medicine's Liabilities and Shareholders Equity amounted to $341.6 million in FY2024, which was down 31.57% from $499.2 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Liabilities and Shareholders Equity registered a high of $677.5 million during FY2021, and its lowest value of $341.6 million during FY2024.
  • In the last 3 years, Editas Medicine's Liabilities and Shareholders Equity had a median value of $499.2 million in 2023 and averaged $451.7 million.
  • In the last 5 years, Editas Medicine's Liabilities and Shareholders Equity rose by 18.32% in 2021 and then plummeted by 31.57% in 2024.
  • Editas Medicine's Liabilities and Shareholders Equity (Yearly) stood at $572.6 million in 2020, then increased by 18.32% to $677.5 million in 2021, then decreased by 24.08% to $514.3 million in 2022, then declined by 2.95% to $499.2 million in 2023, then tumbled by 31.57% to $341.6 million in 2024.